StreetInsider.com News Articles

FibroBiologics ships third CYWC628 batch to Australia for DFU trial

Thu, 27 Aug 2026 08:31:01 -0400

FibroBiologics, Inc. (Nasdaq: FBLG) announced the release and shipment of a third batch of its investigational drug product CYWC628 to Australia, where the company is conducting an ongoing Phase 1/2 clinical trial in patients with diabetic foot ulcers (DFUs).

According to a press release, the batch was manufactured in accordance with current Good Manufacturing Practices (cGMP) and passed required safety and quality testing prior to release for clinical use.

Pete O'Heeron, founder and CEO of FibroBiologics, said the company anticipates "reporting statistically significant interim data of primary outcomes in the second half of 2026."

CYWC628 is an investigational topically administered allogeneic fibroblast cell-based

FibroBiologics ships third CYWC628 batch to Australia for DFU trial

Thu, 27 Aug 2026 08:31:01 -0400

Pete O'Heeron, founder and CEO of FibroBiologics, said the company anticipates "reporting statistically significant interim data of primary outcomes in the second half of 2026."

CYWC628 is an investigational topically administered allogeneic fibroblast cell-based

FibroBiologics Releases Third Batch of CYWC628 Drug Product for Phase 1/2 Diabetic Foot Ulcer Clinical Trial

Thu, 27 Aug 2026 08:30:00 -0400

HOUSTON, Aug. 27, 2026 /PRNewswire/ -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics" or the "Company"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced the release of the third batch of its CYWC628 drug product and its shipment to Australia in support of the ongoing Phase 1/2 clinical trial in patients with diabetic foot ulcers (DFUs). The batch was manufactured in accordance with current Good Manufacturing Practices (cGMP) and

FibroBiologics Releases Third Batch of CYWC628 Drug Product for Phase 1/2 Diabetic Foot Ulcer Clinical Trial

Thu, 27 Aug 2026 08:30:00 -0400

FibroBiologics Releases Third Batch of CYWC628 Drug Product for Phase 1/2 Diabetic Foot Ulcer Clinical Trial

Thu, 27 Aug 2026 08:30:00 -0400

FibroBiologics Releases Third Batch of CYWC628 Drug Product for Phase 1/2 Diabetic Foot Ulcer Clinical Trial

Thu, 27 Aug 2026 08:30:00 -0400

FibroBiologics regains Nasdaq compliance for bid price rule

Wed, 26 Aug 2026 08:30:28 -0400

FibroBiologics, Inc. (Nasdaq: FBLG) announced it received confirmation from The Nasdaq Stock Market LLC on August 25, 2026, that the company has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2).

According to a press release, the Houston-based clinical-stage biotechnology company is now in compliance with all Nasdaq listing standards. Its common shares will continue to trade on the Nasdaq Capital Market under the ticker symbol "FBLG."

FibroBiologics regains Nasdaq compliance for bid price rule

Wed, 26 Aug 2026 08:30:28 -0400

FibroBiologics regains Nasdaq compliance for bid price rule

Wed, 26 Aug 2026 08:30:28 -0400

FibroBiologics regains Nasdaq compliance for bid price rule

Wed, 26 Aug 2026 08:30:28 -0400

FibroBiologics Regains Compliance with Nasdaq Trading Rules